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Transcriptional Activation of Placental Growth
Factor by the Forkhead/Winged Helix
Transcription Factor FoxD1
Results and Discussion
Identification of BF-2 Target Genes by Using High-
Density Oligonucleotide Microarrays
To identify stromal signals regulated by BF-2, we estab-
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showing significant 4-fold induction at 24 hr in two4 Department of Neurology independent replicates (p  0.001) and consistent
Brigham and Women’s Hospital change over the time course studied were identified
and Harvard Medical School as potential BF-2 target genes and were subjected to
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5 Department of Physics Three genes were identified by microarray hybridiza-
Wesleyan University tion and were confirmed to be induced by BF-2 by using
Middletown, Connecticut 06459 Northern blotting (Figure 1): PlGF, a member of the VEGF
family, which cooperates with VEGF itself in mediating
angiogenesis during wound healing and tumorigenesis
[3]; heparin binding Epidermal Growth Factor (HB-EGF);
Summary and the bHLH protein G0S8. We chose to characterize
PlGF in greater detail, since it was induced by BF-2 in
Stromal-epithelial interactions play an important role all cell lines tested and it encodes a secreted growth
in renal organogenesis [1]. Expression of the forkhead/ factor, whose role in embryonic kidney development
could most readily be validated by using in vitro assays.winged helix transcription factor FoxD1 (BF-2) is re-
stricted to stromal cells in the embryonic renal cortex,
Induction of PlGF by BF-2but it mediates its effects on the adjacent ureteric bud
Induction of PlGF rapidly followed that of BF-2, withand metanephric mesenchyme, which fail to grow and
increased expression within 12 hr after the removal ofdifferentiate in BF-2 null mice [2]. BF-2 is therefore
tetracycline (Figure 1C). Two well-characterized PlGFlikely to regulate transcription of factors secreted by
isoforms, PlGF1 and PlGF2, derived from alternativestromal cells that modulate the differentiation of
splicing, have been identified in humans: compared withneighboring epithelial cells. Here, we used cells with
PlGF1, PlGF-2 contains 21 additional amino acids at itsinducible expression of BF-2, combined with microar-
C terminus that confer heparin binding activity [4].ray analysis, to identify Placental Growth Factor (PlGF),
Mouse cells express only one transcript, homologousa Vascular Endothelial Growth Factor (VEGF) family
to PlGF-2. RT-PCR analysis of BF-2-inducible HeLa cellsmember previously implicated in angiogenesis, as a
demonstrated comparable induction of both PlGF-1 anddownstream target of BF-2. BF-2 binds to a conserved
PlGF-2 (data not shown).
HNF3 site in the PlGF promoter and activates tran-
To confirm that PlGF was also induced by BF-2 in a
scription. PlGF is precisely coexpressed with BF-2, physiologically relevant cell type, we established tetra-
both temporally and spatially, within the developing cycline-regulated expression of BF-2 in RSTEM cells, a
renal stroma, and it is completely absent in BF-2 null rat cell line derived from undifferentiated renal mesen-
kidney stroma. Addition of PlGF to in vitro kidney organ chyme at E12.5 [5]. Consistent with its metanephric mes-
cultures stimulates branching of the ureteric bud. Our enchymal origin, RSTEM cells do not express endoge-
observations indicate that PlGF is a direct and physio- nous BF-2. Expression of BF-2 in RSTEM cells also led
logically relevant transcriptional target of BF-2. The to prompt induction of endogenous rat PlGF (Figure 1B).
contribution of PlGF toward stromal signals that regu- The other BF-2 target genes identified in HeLa cells,
late epithelial differentiation suggests novel functions HB-EGF and G0S8, are already expressed at high levels
for a growth factor previously implicated in reactive in RSTEM cells, and no further induction was observed
following BF-2 expression.angiogenesis.
Activation of the PlGF Promoter by BF-2
To determine whether PlGF constitutes a direct tran-*Correspondence: haber@helix.mgh.harvard.edu
6These authors contributed equally to this work. scriptional target of BF-2, we cloned its putative up-
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Figure 1. Induction of PlGF mRNA by BF-2
(A) Summary of genes found to be upregulated by microarray analysis and confirmed by Northern blotting following inducible expression of
BF-2 in HeLa 24-43 cells. The array hybridization signal is shown for RNA extracted 0, 6, 12, 18, and 24 hr following tetracycline withdrawal
(an asterisk denotes average values from duplicate experiments). The fold change from 0 to 24 hr is calculated for array hybridization and
Northern blotting results. (Upper panel) Inducible expression of BF-2, demonstrated by Western blot analysis of HeLa 24-19 cells grown in
the presence or absence of tetracycline (tet or tet).
(B) Representative Northern blots showing induction of Placental Growth Factor (PlGF) coincident with that of BF-2, 24 hr following the
withdrawal of tetracycline in HeLa 24-43 and in the rat kidney precursor RSTEM cells (GAPDH; loading control).
(C) Time course of PlGF induction following BF-2 expression in HeLa 24-43 cells grown in the presence of tetracycline or at sequential intervals
following drug withdrawal.
stream regulatory region into the promoterless lucifer- the possibility of additional responsive elements. Taken
together, these observations suggest that BF-2 can bindase vector, pGL3. Luciferase activity was examined
following transient cotransfection of the reporter con- directly to the HNF3 consensus sequence in the PlGF
promoter and can thus mediate transcriptional acti-struct and a CMV-driven BF-2 expression vector into
HeLa cells. A reporter construct containing a 3.5 kb vation.
genomic fragment (1 to 3459) upstream of the PlGF
translational start site was activated 13-fold by BF-2. Coexpression of PlGF and BF-2 in Developing
Kidney StromaProgressive deletion of this region indicated the pres-
ence of a major BF-2-responsive element within a 250 To determine whether the induction of PlGF by BF-2 in
cultured cells reflects a physiologically significant inter-bp fragment, between 1653 and 1400. The reporter
construct containing this fragment was activated 19- action, we used RNA in situ hybridization to examine
mouse embryonic kidneys at days E12.5 and E14.5 forfold by BF-2 (Figures 2A and 2B). Deletion of this region
significantly suppressed BF-2 induction of the reporter. the expression pattern of BF-2 and PlGF. As previously
reported, BF-2 is expressed in a population of stromalElectrophoretic mobility shift assays (EMSA) demon-
strated specific binding of bacterially produced BF-2 cells surrounding the nephrogenic mesenchyme and
ureteric bud in E12.5 kidneys (Figures 3A and 3B) [2].protein to the 250 bp fragment; this binding allows fur-
ther mapping of the binding site (Figure 2C). BF-2 is Remarkably, PlGF is expressed at a high level in the
same ring of cells surrounding the metanephric mesen-known to bind a similar DNA consensus sequence as its
close homolog, the forkhead/winged helix transcription chyme and the ureteric bud (Figures 3E and 3F). Low
levels of PlGF are also present in some mesenchymalfactor HNF3, although no transcriptional targets have
been identified [6]. A single putative HNF3 binding site cells that do not express BF-2. In E14.5 kidneys, the
nephrogenic zone is limited to the outer edge of theis present within the BF-2-responsive region (1483
to 1502). Indeed, EMSA showed that BF-2 protein developing kidney, and the epithelial cells derived from
the mesenchyme have undergone a series of morpho-binds to a genomic fragment containing the wild-type
sequence, but not to one in which the consensus binding logical changes, forming comma- and S-shaped bodies
and some early glomeruli. At this stage, BF-2 and PlGFsequence had been mutated (Figure 2D). Deletion of this
element shows a dramatic reduction in transactivation, are coexpressed in the cortical stroma that surrounds
the developing kidney (Figures 3C and 3G). The develop-although some persistent activation by BF-2 suggests
Induction of PlGF by BF-2 in Renal Stroma
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Figure 2. Transcriptional Activation of the PlGF Promoter by BF-2
(A) A schematic representation of promoter-less luciferase reporters containing fragments of the human PlGF promoter. The nucleotide (nt)
position of the HNF3 binding site (box) and the transcriptional start site (arrow) are shown with respect to the first ATG.
(B) Fold induction of PlGF reporters (0.05 g) by cotransfected CMV-BF-2 (0.15 g) in HeLa cells. Renilla plasmid (0.01 g) was cotransfected
to standardize transfection efficiency, and equal amounts of total DNA were used in each transfection. Standard deviation is derived from at
least three independent experiments.
(C) Electrophoretic mobility shift assay (EMSA) analysis, using GST-BF-2 protein incubated with the minimal BF-2-responsive region of the
PlGF promoter (1653 to 1401 nt), identified by luciferase reporters with progressive genomic deletions. The arrows indicate the specific
protein:DNA complexes, effectively competed by the addition of unlabeled double-stranded oligonucleotide (50).
(D) EMSA analysis of BF-2 binding to the wild-type, but not to the mutant HNF3-responsive element.
ment of glomeruli is accompanied by invasion and prolif- hybridization (Figure 3D). BF-2(/) kidneys show de-
fects in branching of the ureteric bud and in the differen-eration of endothelial cells. PlGF is also present in devel-
oping and mature glomeruli, and its presence suggests tiation of condensed mesenchyme. However, the distri-
bution and amount of stroma is comparable to that ofthat it also contributes to recruiting endothelial precur-
sor cells into the glomerular vascular cleft (Figure 3G). wild-type kidney [2]. Remarkably, PlGF expression is
undetectable in the kidney stroma of BF-2(/) em-In developing glomeruli, as in some mesenchymal cells,
expression of PlGF is presumably regulated by factors bryos (Figure 3H); this finding indicates that expression
of PlGF in embryonic kidney stroma is dependent uponother than BF-2. In contrast to the restricted expression
of PlGF in the differentiating kidney, its homolog VEGF the presence of BF-2. Low levels of PlGF expression
are present in some mesenchymal cells, where it is pre-is expressed throughout the nephrogenic mesenchyme
in E12.5 kidneys, but only weakly in the ureteric epithe- sumably regulated by factors other than BF-2. The ex-
pression of VEGF is not changed in BF-2(/) kidneyslium (Figures 3I and 3J). By E14.5 kidneys, VEGF ex-
pressed primarily in the developing glomeruli and tubu- (Figure 3L).
In examining the expression patterns of the PlGF re-lar structures (Figure 3K). Thus, BF-2 and PlGF are
unique in their precise temporal and spatial coexpres- ceptors Flk-1, Flt-1, and Neuropilin-1 in the developing
kidney (see the Supplemental Results), we found a highsion in the embryonic renal stroma.
To determine whether BF-2 expression is required for level of Neuropilin-1 expression within the embryonic
ureteric epithelium and nephrogenic mesenchyme,the expression of PlGF in the embryonic renal stroma,
we analyzed BF-2 null kidneys by using RNA in situ whereas Flk-1 and Flt-1 are restricted to vascular struc-
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Figure 3. Expression of BF-2, PlGF, and VEGF in Developing Mouse Kidney
(A) RNA in situ hybridization, demonstrating expression of BF-2 transcript in a population of stromal cells surrounding the E12.5 kidney.
(B) Higher magnification, showing that BF-2 is expressed specifically in the cells surrounding the ureteric bud (UB) and condensing mesenchyme.
UB and mesenchyme are identified by staining for Wnt-11 and Wnt-4, respectively (not shown).
(C) At day E14.5, BF-2 expression is restricted to the cortical stroma of the kidney.
(D) Absent expression of BF-2 in kidney from the mouse knockout.
(E and F) Expression of PlGF in the stromal compartment of the E12.5 kidney parallels that of BF-2.
(G) At day E14.5, PlGF is present, along with BF-2, in the cortical stroma, as well as in developing glomeruli (g).
(H) Absent expression of PlGF in stroma cells of BF-2(/) mice (overexposed).
(I) In contrast to PlGF, expression of VEGF mRNA is present diffusely throughout the developing kidney.
(J) High magnification shows VEGF expression in the stroma and nephrogenic mesenchyme.
(K) At day E14.5, VEGF expression is weak in the outer nephrogenic zone, including the stroma, but high in developing glomeruli (g) and renal
tubules (t).
(L) Unaltered expression of VEGF in BF-2(/) kidneys.
tures. These observations raise the possibility that Neu- the major mesenchymal inductive signal for ureteric bud
branching (Figure 4) [8].ropilin-1 may mediate a direct effect of PlGF on renal
differentiation.
Conclusions
Here, we have used heterologous cells with tightly regu-Induction of Ureteric Bud Branching by PlGF
in Embryonic Kidney Organ Cultures lated, inducible expression of BF-2, together with mi-
croarray-based expression profile analysis, to identifyOrgan cultures of E11.5 mouse kidney offer an invalu-
able assay of renal differentiation in which to test the PlGF as a specific developmentally regulated transcrip-
tional target of BF-2, likely to contribute to stroma-direct effect of recombinant growth factors. At this
stage, the ureteric bud has just invaginated the mesen- derived proliferation and differentiation signals. PlGF
has previously been linked to pathological and reactivechyme, but no branching has occurred. The ureteric bud
grows and branches during incubation in vitro, and the angiogenesis [3]; our observations point to a new role
in stimulating branching of the ureteric bud. By virtuemetanephric mesenchyme forms aggregates that con-
vert to epithelial cells [7]. To test for functional properties of its expression in the ureteric bud, the receptor Neu-
ropilin-1 is a strong candidate to mediate PlGF signalingof PlGF in this renal differentiation assay, we examined
organ cultures incubated for 40 hr in the presence or from stromal cells during ureteric bud branching. In ad-
dition, PlGF may also contribute to kidney differentiationabsence of recombinant mouse PlGF. Cultures were
then stained with an antibody to pan-cytokeratin, which indirectly through its effects on endothelial cells carrying
the Flt-1 and Flk-1 receptors. Epithelial and vascularserves as a measure of ureter branching. In multiple
experiments, the addition of PlGF increased the number differentiation appear to be coordinated in organ cul-
tures [9, 10], and VEGF treatment or hypoxic conditionsof terminal buds by nearly 40%, from a mean of 16 (2.9)
to 22(3.1) (n	 24) (Figure 4). This effect is comparable enhance differentiation of both endothelial and epithelial
cells [11, 12]. Thus, PlGF or PlGF/VEGF heterodimersin magnitude to that seen with the addition of GDNF,
Induction of PlGF by BF-2 in Renal Stroma
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